1Y Close · As of Aug 26, 2026
Humedix operates in the Pharmaceuticals sector.
Legal name: Humedix Co., Ltd.
In fiscal year 2021, Humedix (200670) reported revenue of 111.0 billion KRW, up 12.7% from 98.5 billion KRW a year earlier.
Operating profit was 16.0 billion KRW and net income was 10.1 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 289.2 billion KRW, with a P/B of 0.97.
These figures can be verified in the DART filing (receipt no. 20260320000801).
Recent Filings
Corporate Briefing (IR)
Semi-Annual Report (2026.06)
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Corporate Briefing (IR) |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-11 | 중간(분기)배당을위한주주명부폐쇄(기준일)결정 |
| 2026-08-11 | Dividend Decision (Quarterly Dividend) |